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Evodia rutaecarpa is commonly used as an anti-inﬂammatory herbal remedy in traditional Chinese medicine. In this study, the
ethanol extract of E. rutaecarpa (ER) and three major quinazoline alkaloids dehydroevodiamine (DeHE), evodiamine (Evo)
and rutaecarpine (Rut), isolated from ER were employed to study their inhibitory eﬀects against inﬂuenza A virus (H1N1)-
induced chemokines production in A549 lung epithelial cells as well as on chemokines-evoked cell recruitment in HL-60-
diﬀerentiated macrophages. The results showed that ER was a potent inhibitor of RANTES secretion by H1N1-inoculated A549
cells (IC50:1. 9±0.4μgml −1).Three alkaloids,althoughto diﬀering extents, all concentrationdependent, inhibited H1N1-induced
RANTES production with Evo consistently being the most potent among these active components. ER also moderately and
signiﬁcantly inhibited H1N1-stimulated MCP-1 production in A549 cells. This was mimicked by Evo and Rut, but not DeHE.
In the macrophage recruitment assay, both RANTES and MCP-1 markedly evoked cell migration and this phenomenon was
signiﬁcantly suppressed by ER. Evo and Rut, but not DeHE, also had the ability to inhibit cell migration toward RANTES and
MCP-1, respectively. In summary, three major alkaloids displayed diﬀerent potentials for inhibiting chemokines secretion and
subsequently cell migration, which could partially explain the activity of ER. As an eﬀective agent to suppress H1N1-induced
chemokines production and block chemokine-attracted leukocytes recruitment, E. rutaecarpa and its active components may be
useful in inﬂuenza virus infection-related inﬂammatory disorders.
1.Introduction
An outbreak of infections with a new inﬂuenza A (H1N1)
virus that was ﬁrst detected in the USA and Mexico is
currently ongoing worldwide. The most important fea-
ture of novel inﬂuenza A (H1N1) or avian ﬂu (H5N1)
immunopathogenesisis theappearance ofhypercytokinemia
(cytokine storm) that is characterized by the extreme (exag-
gerated) production and secretion of large numbers and
excessive levels of pro-inﬂammatory cytokines/chemokines.
This phenomenon is blamed on the emergence of lethal
clinical symptoms, such as extensive pulmonary edema,
acute bronchopneumoniae, alveolar hemorrhage, reactive
hemophagocytosis and acute respiratory distress syndrome,
associated with necrosis and tissue destruction. Many
in vitro, in vivo and clinical studies have pointed out
that novel inﬂuenza A/H5N1 viruses are very strong
inducers of various cytokines and chemokines in both
humans and animals [1], for example, RANTES (regu-
lated on activation, normal T cell expressed and secreted)
is a potent chemoattractant for monocytes/macrophages,
basophils and T cells and has been found in the nasal
secretions of patients suﬀering from upper respiratory
tract infection with inﬂuenza virus, parainﬂuenza virus
and adenovirus [2, 3]. Macrophage chemotactic protein-
1 (MCP-1), a member of the CC chemokines subfamily
recruiting and activating mainly monocyte/macrophages in
inﬂammatory sites, is also reported to play a crucial role
in the progression of chronic inﬂammation and multiple
sclerosis after viral infection [4, 5]. These chemokines
are rapidly induced following infection, and they bind
to their receptors to initiate immune cell migration and
inﬁltration. Precisely regulating chemokine expression and
subsequent cellular responses likely optimize protection2 Evidence-Based Complementary and Alternative Medicine
and minimize the deleterious eﬀects of uncontrolled viral
invasion.
Traditional Chinese medicine has long been used as a
remedy against infectious diseases in China. For example,
“Wu-Chu-Yu,” the unripe fruit from Evodia rutaecarpa,
has long been utilized in traditional Chinese medicine for
treating pathogen infections (e.g.; pneumonia bacteria) and
inﬂammation-related disorders such as eczema, ulcerative
stomatitis and etcetera [6]. Several alkaloids with biological
activity have been identiﬁed in E. rutaecarpa including three
major alkaloids: dehydroevodiamine (DeHE), evodiamine
(Evo) and rutaecarpine (Rut) [7]. Pharmacological investi-
gations have revealed diﬀerent extracts of E. rutaecarpa,a n d
its chemical constituents display many biological activities
related to inﬂammation, for example, antinociception, anti-
inﬂammation, immune modulation, nitric oxide (NO) inhi-
bition [8], protection against endotoxin shock in rats and
anti-inﬂammatory activity in human skin [9–14]. However,
little is known about their potential against viral infection-
mediated chemokine secretion and cell inﬁltration.
In this study, we attempted to set up two inﬂammation-
related cellular models including (i) activation of human
lungepithelial cells by inﬂuenza virus-mediated induction of
chemokines(RANTESand MCP-1) and (ii)cell migration in
response to chemokins in HL-60-diﬀerentiated macrophage,
which isacrucialdeterminantofleukocytetraﬃcking,astwo
parameters for evaluating the anti-inﬂammatory potential of
the ethanol extract of E. rutaecarpa (ER) and simultaneously
correlating its anti-inﬂammatory activities with three major
alkaloids (DeHE, Evo and Rut). We found that E. rutaecarpa
and its active components especially Evo and Rut, may be
useful in viral (inﬂuenza A) infection-related inﬂammatory
disorders by limiting chemokine secretion and the early
phases of macrophage inﬁltration.
2.Methods
2.1. Extract Preparation and Alkaloids Isolation. Dried E.
rutaecarpa (Juss.) Benth was purchased from a local drug
store in Taipei and identiﬁed by Mr C. J. Chou (Fellow in
Pharmacognosy, Principal Investigator in National Research
Institute of Chinese). ER was prepared as described in our
previous reports [14]. After being vacuum dried, the ER was
re-dissolved in dimethyl sulfoxide (DMSO) as a 10mgml
−1
stock solution. Three major components, DeHE, Evo and
Rut, were puriﬁed from the ER [15, 16]. Their identities
were conﬁrmed by comparing their NMR and IR spectra
with those reported in the literature [17]. These drugs were
all dissolved in DMSO as stock solutions of 10mM. The
ﬁnal concentration of DMSO in the reaction buﬀer was
<0.25%, and at that concentration, it showed no signiﬁcant
cytotoxicityorbiologicalactivity ascomparedwith drug-free
samples as reported in our previous report.
2.2. Cell Culture, Virus Preparation and Infection Pro-
tocol. Adherent Madin-Darby canine kidney II (MDCK-
II) purchased from Food Industry Research and Devel-
opment Institute (Hsinchu, Taiwan) cells were grown in
DMEM supplemented with 10% heat-inactivated, virus-
and mycoplasma-free fetal calf serum (FCS), 100Uml
−1
of penicillin, 100μgml
−1 of streptomycin and 2mM l-
glutamine (Biological Industries, Israel). Human alveolar
epithelial cells (A549) (Industry Research and Development
Institute, Hsinchu, Taiwan) were grown in the RPMI 1640
medium (Gibco BRL, USA) supplemented with 10% heat-
inactivated FCS, 100Uml
−1 of penicillin, 100μgml
−1 of
streptomycin, 2mM l-glutamine and non-essential amino
acid. Inﬂuenza A virus strain A/PR/8/34 (H1N1) was kindly
donatedby DrC. H.Chan, Department ofMicrobiologyand
Immunology, SchoolofMedicine, ChungShan MedicalUni-
versity,Taichung.TheviruswaspropagatedinMDCKcellsin
serum-free DMEMcontainingporcine trypsin (Sigma,USA)
to facilitate infection of cells at 37◦C. Virus production was
followed by titrationof viral hemagglutinin(HA)[18].Virus
seed was stored at aliquots of 10ml at −70◦C.
For the assay, A549 cells were grew in 24-well plastic
tissue culture plates (Costar, USA). Conﬂuent monolayers
of A549 cells were inoculated with H1N1 at a multiplicity
of infection (MOI) of 1 plaque forming unit (PFU)/cell
in the serum-free RPMI 1640 medium at 37◦C. After a
1-h absorption period, the virus-containing medium was
removed, washed with PBS and furthermore incubated in
medium containing 1% FCS for 72h in the absence or
presence of various concentrations of ER or three major
alkaloids, respectively. Supernatants were collected at 72h
a n da s s a y e df o rh u m a nR A N T E Sa n dM C P - 1[ 19]. The A549
monolayers in the culture plate were separated from the
medium, washed with PBS to remove the dead cells resulting
from herbal extracts treatment and the cell viability was
determined by staining with MTT (see below).
2.3. Cell Viability. Cell respiration, an indicator of cell
viability, was determined by the mitochondrial-dependent
reduction of 3-(3,4-dimehyl-thiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) to formazan. The extent of
the reduction of MTT to formazan within the cells was
quantiﬁed by measuring the optical density at 550nm.
2.4. Chemokines Measurement. Cultured supernatants col-
lected from uninfected and infected A549cells, orbefore and
after tested agent treatment, were assayed for RANTES and
MCP-1 using commercially available ELISA kits according to
the procedures provided by the manufacture (Chemicon).
All samples were determined in triplicate. The standard
concentrations range for RANTES were 0, 31.2, 62.5, 125,
250, 500 and 1000pgml
−1, for MCP-1 were 0, 15.6, 31.2,
62.5, 125, 250, 500 and 1000pgml
−1, respectively.
2.5. Culture and Diﬀerentiation of HL-60 Cells. Human
promyelocytic HL-60 cells (ATCC) were grown in the
RPMI 1640 medium supplemented with 10% FCS, 0.1mM
nonessential amino acids, 100Uml
−1 penicillin and
100μgml
−1 streptomycin at 37◦C under a humidiﬁed
95%/5% (v/v) mixture of air and CO2. For induced cells to
undergo diﬀerentiation along the monocyte/macrophage
lineage, the cells were seeded onto dishes at 5×105 cellsml
−1
and treated with PMA at doses of 2nM. After 48h of
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adherent cells were harvested using trypsin/EDTA and used
to assess the chemotactic migration.
2.6. Chemotactic Migration. Cell migration was assessed
using a 24-well chemotaxis chamber with a membrane pore
size of 5μm (Transwell, Corning Costar). Ninety microliters
of cell suspension (2×107 cellsml
−1) was added to each
of the upper wells in the presence of 10μl PBS or various
concentrations of ER or alkaloids for 30 min. Recombinant
RANTES and MCP-1 proteins (R&D, USA) were added
to the lower well of the chamber to assess chemoattractic
activity. Then the entire chamber was incubated at 37◦C
for 6h to initiate migration. Non-migrated cells were wiped
oﬀ with a cotton swab and then the ﬁlter was ﬁxed
and stained with hematoxylin (Sigma) to deﬁne the cell
nuclei. Chemotaxis was assessed by counting the number
of migrated cells in ﬁve (at 400×magniﬁcation) random
microscopy ﬁelds per well [20, 21]. All experiments were
performed in triplicate. Chemokines-induced cell migration
minus spontaneous migration in PBS served as control and
was designated as 100% migration for each experiment.
2.7. Statistical Analysis. All values in the text and ﬁgures
represent means±SE. Data were analyzed by un-paired Stu-
dent’s t-test. P <.05 was considered statistically signiﬁcant.
3.Results
3.1. ER and Three Quinazoline Alkaloids Suppressed H1N1-
Induced RANTES and MCP-1 Production in Human Lung
Epithelial Cells. RANTES concentration was very low in
the uninfected cell supernatant after a 72-h culture
period. Infection of the A549 cells with inﬂuenza A/H1N1
evoked a seriously enhanced secretion of RANTES from
basal (23±9pgml
−1)) to 1207±114pgml
−1 measured
at 72h. At the non-cytotoxic doses (1–100μgml
−1), ER
exerted a consistent inhibitory responsiveness on H1N1-
stimulated RANTES accumulation with an ID50 value of
1.9±0.4μgml
−1 (Figure 1(a)). Three major components
(DeHE, Evo and Rut) at concentrations ranging from 1 to
30μM, although to diﬀering extents, all inhibited H1N1-
induced RANTES production. Figure 1(b) shows that Evo
( 1 ,3 ,1 0a n d3 0 μM) treatment inhibited virus-evoked
RANTESproduction in a concentration-dependent manner:
statistical signiﬁcance was observed beginning at 1μM( P
<.05) and suppression approaching basal was achieved by
30μME v o( I C 50:2 . 1±0.7μM). Rut also dose-dependently
inhibited virus-evoked RANTES release with an IC50 of
8.3±1.9μM, althoughinhibitionobtained by30μMw a sn o t
complete.DeHE,however,wastheleastpotentofthesedrugs
in reducing (around 20% of inhibition at 30μM) H1N1-
induced RANTES production in A549 cells. The data of
cell viability assessed by MTT assay showed that all tested
agents at concentrations used did not express signiﬁcant
cytotoxicity.
A signiﬁcant increase in MCP-1 production was also
noted after H1N1 infection. Figure 2(a) shows that MCP-1
concentration was increased from basal (198±21pgml
−1)
to 1357±131pgml
−1 at 72h post-infection and such an
induction could be suppressed by ER concentration depen-
dently. As with RANTES production, Evo was the most
potent in suppressing MCP-1 formation with an IC50 value
of 8.7±1.3μM( F i g u r e2(b)) .I nt h ec a s eo fR u t ,al o wd o s e
(1 and 3μM) failed to, but a higher dose (10 and 30μM)
signiﬁcantly reduced H1N1-evoked MCP-1 secretion. The
trend of inhibition was observed with DeHE, but not to a
level of statistical signiﬁcance.
3.2. ER and Three Quinazoline Alkaloids Reduced RANTES-
and MCP-1-Induced Chemotactic Migration of Macrophages.
Figure 3(a) s h o w st h a tR A N T E Sa tc o n c e n t r a t i o n sr a n g i n g
from 10 to 1000 ngml
−1 was able to evoke cell migration of
HL-60-diﬀerentiatedmacrophageswith apeakactivity noted
at 100ngml
−1 (total migrated cell number of 223±31).
Time course analysis from a preliminary study also showed
an increase in cell migration with time, reaching a maximum
between 4 and 6h. Therefore, 100ngml
−1 of RANTES and
a migration period of 6h were selected for further exper-
iments. The results showed that ER alone (1–100μgml
−1)
did not inﬂuence spontaneous transmigration (data not
shown), but concentration dependently inhibited RANTES-
stimulated chemotactic migration with an IC50 value of
79.2±8.4μgml
−1 (Figure 4(a)). None of the concentrations
of ER used reduced cell viability (>95%), as assayed by MTT
exclusion. Further, we studied the eﬀect of three alkaloids
on RANTES-induced migration of HL-60-diﬀerentiated
macrophages. The result showed that Evo and Rut have
the ability to inhibit RANTES-evoked cell migration in a
concentration-dependent manner (Figure 4(b)). In contrast,
DeHE failed to cause such a phenomenon.
Whether HL-60-diﬀerentiated macrophages could
migrate toward MCP-1 and the eﬀects of ER and its active
components on this phenomenon were further studied.
Compared with the unstimulated condition (displayed
spontaneous migration with a total cell number of 68±9),
macrophages treated with MCP-1 evoked signiﬁcantly
chemotactic migration with peak activity occurring at
100ngml
−1 (total migrated cell number of 194±22),
pointing out that MCP-1 is a chemotactic agent in
inducing migration of HL-60-diﬀerentiated macrophages
(Figure 3(b)). We next examined whether ER could aﬀect
the responsiveness of macrophages to MCP-1. We found
that ER also suppressed MCP-1-evoked cell migration,
although to a lesser extent than the suppressed RANTES
response (Figure 5(a)). The IC50 value for ER to inhibit
MCP-1-induced migration was 235.1±11.6μgml
−1.E x c e p t
for DeHE, there were trends for the others to inhibit
MCP-1-evoked cell migration (Figure 5(b)). The IC50
levels for Evo and Rut to inhibit such a response were
67.2±9.5 and 218.0±25.4μM, respectively. Nevertheless,
these trends were less eﬀective than inhibiting migration
toward RANTES.
4.Discussion
Inﬂuenza A virus attacks upper respiratory tract and
replicates in epithelial cells resulting in the production of4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Eﬀects of ER (a) and three major quinazoline alkaloids (b) on H1N1-stimulated RANTES production by A549 human bronchial
epithelial cells. RANTES concentration was determined at 72h after virus inoculation. Data reported are mean±SE of four independent
experiments, each performed in triplicate. ∗P < .05 and ∗∗P <.01 indicate signiﬁcantdiﬀerences as compared withH1N1 inoculationalone.
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Figure 2: Eﬀects of ER (a) and three major quinazoline alkaloids (b) on H1N1-stimulated MCP-1 production by A549 human bronchial
epithelial cells. RANTES concentration was determined at 72h after virus inoculation. Data reported are mean±SE of ﬁve independent
experiments, each performed in triplicate. ∗P < 0.05 and ∗∗P <.01 indicate signiﬁcant diﬀerences as compared with H1N1 inoculation
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Figure 3: Concentration-related cell migration of HL-60-
diﬀerentiated macrophages in response to RANTES (a) and MCP-1
(b). Cells were placed in the upper well and chemokines were
added into the lower wells of the chamber for the assessment of
migration activity. The entire chamber was then incubated for 6h
at 37◦C. Migration was assessed by counting migrated cells in ﬁve
microscopic ﬁelds per well at 400×magniﬁcation. Data reported
are mean±SE of six independent experiments, each performed
in triplicate. ∗P <.05 and ∗∗P <.01 indicate degrees of statistical
signiﬁcance of diﬀerence as compared to un-stimulated cells.
cytokinesand chemokinesthatrecruitleukocytestoinﬁltrate
the infected tissues. Severe inﬂuenza A virus infection
may cause complicated secondary bacterial infection and
inﬂammatory response, lung inﬁltration and ﬁbrosis, failure
of respiration and even death. The new drug development
strategy pointed to preventing macrophage invasion by
interfering with chemokine secretion; chemokine receptors
expression or cell migration may serve as potential agents
to prevent deterioration and interrupt the pathogenesis
following viral infection. After H1N1 infection, the alveolar
epithelial cells can produce various kinds of chemokines to
attract immune cell (such as monocyte/macrophage) [2–
5]. RANTES and MCP-1 belonging to the CC chemokines
family are the two most potent chemoattractants for mono-
cyte/macrophage. In our preliminary study, we have found
that after H1N1 inoculation, the production of these two
chemokines by A549 cells was more pronounced than
the other CC chemokinse such as MIP-1α and MIP-1β
[19]. Furthermore, MCP-1 and RANTES could evoke more
signiﬁcantchemotacticmigrationthantheotherchemokines
did when applying the recombinant chemokine proteins to
the lower chamber of the transwell [19]. Therefore, MCP-
1 and RANTES were chosen as two candidates to assess the
eﬀects of E. rutaecarpa and its bioactive components in the
present study.
Evodiae fructus (known in Chinese as wu-chu-yu), is
the dried, nearly ripe fruit of E. rutaecarpa (Juss.) Benth.
(Rutaceae). It is oﬃcially listed in the Chinese Pharma-
copoeia and is used as an analgesic, anti-emetic, astringent
and anti-inﬂammatory agent and for treating hypertension.
It is also used as a remedy for gastrointestinal disorders
(abdominal pain and dysentery), headaches, amenorrhea
and post-partum hemorrhage; and for treating bacterial
infections (e.g, pneumonia bacteria) and inﬂammation-
related disorders such as eczema and ulcerative stomatitis
[22]. Evodia rutaecarpa had been used for treating infectious
diseases because of the anti-inﬂammatory properties of its
active components. Early in 1999, Moon et al. reported
that Rut is a new class of COX-2 inhibitor [23]. We also
found that DeHE and Evo could suppress LPS-induced NO
production [8]a n dE. rutaecarpa was able to protect against
circulation failure and organ dysfunction in endotoxaemic
rats through modulating nitric oxide release [9]. Recently,
Ko et al. found that the ER and its four bioactive com-
ponents (including DeHE, Evo and Rut) all displayed anti-
inﬂammatory activities, which could be partially explained
by their diﬀering potentials for inhibiting NADPH oxidase-
dependent reactive oxygen species and/or iNOS-dependent
NO production in activated inﬂammatory cells [14]. On
the other hand, Liu et al. [24] reported that Evo repressed
not only COX-2 and inducible nitric oxide synthase (iNOS)
expression but also HIF-A accumulation in a concentration-
dependent manner under hypoxic conditions [24]. Further-
more, Yarosh et al. [13] found ER extract was a potent
inhibitor of UVB-inducedpgE2 released by keratinocytes
in culture. Twice daily application of 0.1%–1% ER extract
for 2 weeks also signiﬁcantly inhibited erythema following
a methyl nicotinate (an NO inducer) challenge in human
skin.
Here, we report that E. rutaecarpa and three major alka-
loids (DeHE, Evo and Rut) isolated from this herb were able
to inhibit pro-inﬂammatory chemokines production after
H1N1 infection and subsequently chemotactic migration.
We found that ER (the ethanol extract of E. rutaecarpa)
had the ability to abrogate RANTES and MCP-1 production
by H1N1-infected human alveolar epithelial cells (A549).
Three major alkaloids also displayed diﬀerent abilities to
suppress chemokines secretion with the inhibitory order of
Evo > Rut > DeHE, indicating that the coordination by
Evo and Rut may signiﬁcantly contribute to the chemokine
inhibitory eﬀect by ER. Direct toxicity of all tested com-
pounds on A549 cells is an unlikely explanation for their
inhibitory eﬀects on chemokines production base without
any clear cytotoxicity as measured by the MTT assay. In
fact, we have investigated the eﬀects of water extract and
ER on H1N1-induced chemokines (RANTES and MCP-1)6 Evidence-Based Complementary and Alternative Medicine
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Figure 4: Eﬀects of ER (a) and three major alkaloids (b) on RANTES-induced migration of HL-60-diﬀerentiated macrophages. Cells pre-
incubated with respective tested agents for 30min were plated into the upper wells of the chamber. RANTES (100ngml
−1) was then added
to the lower wells to induce cell migration for 6h. Migration was assessed by counting migrated cells in ﬁve microscopic ﬁelds per well
at 400×magniﬁcations. RANTES-induced cell migration minus spontaneous migration in PBS served as control and was designated as
100%. Data reported are mean±SE of six independent experiments, each performed in triplicate. ∗P <.05 and ∗∗P <.01 indicate degrees
of statistical signiﬁcance of diﬀerence as compared to samples without tested agents treatment.
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Figure 5: Eﬀects of ER (a) and three major alkaloids (b) on MCP-1-induced migration of HL-60-diﬀerentiated macrophages. Cells pre-
incubated with respective tested agents for 30min were plated into the upper wells of the chamber. MCP-1 (100ngml
−1) was then added
to the lower wells to induce cell migration for 6h. Migration was assessed by counting migrated cells in ﬁve microscopic ﬁelds per well at
400×magniﬁcations. MCP-1-induced cell migration minus spontaneous migration in PBS served as control and was designated as 100%.
Data reported are mean±SE of six independent experiments, each performed in triplicate. ∗P <.05 and ∗∗P <.01 indicate degrees of
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secretion in A549 alveolar epithelial cell as well as recom-
binant chemokine proteins-evoked migration of HL-60-
diﬀerentiated macrophages in our preliminary study. Results
showed that ER selectively attenuated H1N1 infection-
evokedRANTRES/MCP-1productionand RANTRES/MCP-
1evokedcellmigration,butthewaterextractofE.rutaecarpa
failed to aﬀect such responsiveness (data not shown). Unlike
DeHE, Evo and Rut, the other two minor components
isolated from ER named Q and S (Chiou et al., unpublished
data), aﬀected neither chemokines production nor chemo-
tactic migration. Thus, we concluded that the eﬀects of ER
and its three major active components (DeHE, Evo and Rut)
on chemokines production and cell migration were not due
to non-speciﬁc false response.
During the inﬂuenza virus infection, viral RNA and
viral proteins have been shown to activate the nuclear
transcription factor NF-κB resulting in many inﬂammatory
genes transcription, including chemokines [25, 26]. Takada
et al. and Choi et al. reported that Evo abolished constitutive
and inducible NF-κB activation by inhibiting IκBk i n a s e
activation [11, 27]. Therefore, the inhibitory mechanisms of
Evo on chemokines production may probably be attributed
to interference with NF-κB activation. Although they con-
sistently reported that Rut did not inhibit NF-κBa c t i v a t i o n ,
whether Rut reduced chemokines expression by aﬀecting the
other transcriptional factors activation remains to be further
studied.
Macrophages play a key role in host defenses against
invading micro-organisms. In response to pathogens,
macrophages migrate along the chemokine gradient toward
the infected tissue and ﬁnally engulf the pathogens by
phagocytosis [28]. However, inappropriate recruitment and
inﬁltration of the infected tissues may subsequently induce
multiple sclerosis. Thus, drugs preventing macrophage
invasion by interfering with chemokines secretion and
subsequently evoking chemotactic migration may serve as
potential agents to interrupt the inﬂammatory pathogenesis
after severe viral infection. Here we report that ER (the
ethanolextractofE.rutaecarpa)wasabletoinhibitRANTES-
induced chemotactic migration of macrophages. Indeed,
inhibition was not only observed with RANTES-induced
migration. Our result indicated that ER also inhibited
cell migration in response to MCP-1, although with less
eﬀectiveness (IC50: 79.2±8.4 versus 235.1±11.6μgml −1).
Data from the present study and our previous publications
[21] all indicated that the dose response for chemokines-
induced cell migration was bell shaped because more higher
concentrations of chemokines did not result in further
increase in migrated cell numbers. Such bell-shaped cell
migration response was also observed in other studies [29,
30].
Because ER inhibited not only RANTES-induced cell
migration but also MCP-1-induced cell migration, it may be
postulated that ER may act as a broad inhibitor to abrogate
inﬂammatory processes attributed to chemokine/cytokine
dysregulation. To evaluate whether the anti-migration eﬀect
of ER was correlated with the three major bioactive compo-
nents,their eﬀectsonbothRANTES-andMCP-1-stimulated
chemotactic migration in macrophages were also deter-
mined. Our results indicated that Evo was consistently the
most potent agent among these components responsible for
the ER’s anti-migration eﬀect and that Rut was accountable
for such inhibition by ER too. It is reasonable that such
activity contributed to the anti-migrating eﬀect by Evo and
RuttowardRANTESandMCP-1,respectively.Wefoundthat
DeHE was the least potent drug throughout the experiment.
Ogasawara et al. reported that Evo has remarkable inhibitory
activity against hepatocyte growth factor (HGF)-induced
migration of tumor cells (colon 26-L5 carcinoma, B16-F10
melanoma and Lewis lung carcinoma) [21–33]. Recently,
Heo et al. examined the inhibitory eﬀect of Evo and Rut
on LIGHT-induced migration in human monocytes, THP-
1. They found that Evo and Rut can inhibit LIGHT-induced
migration by decreasing the expression of CCR1 and CCR2,
two chemokine receptors that recognize RANTES and MCP-
1, respectively [34]. We suggested the action site for DeHE,
Evo and Rut may target inside the cell. To interrupt intracel-
lular signal transductions mediating chemokine production,
chemokinereceptorexpressionorconsequentcellmigration,
these compounds have to penetrate the cell membrane.
According to the dissolved characteristic, Evo and Rut are
lipophilic but DeHE is relatively more hydrophilic. This
means DeHe has more diﬃcultly penetrating the cell.
In conclusion, the anti-inﬂammatory properties of the
ER could be due, at least in part, to the diﬀerent potentials
of its three major alkaloids (DeHE, Evo and Rut) in inhibit-
ing chemokines production and/or chemotactic migration,
although we did not examine the action mechanism about
how DeHE, Evo and Rut repressed chemokines production
and cell migration in detail. Based on our results and other’s
ﬁndings, we suggested that the possible action sites for
these compounds may target inside the cell as showed in
Figures 6 and 7, respectively. Our results indicated that
E. rutaecarpa possesses therapeutic potential through its
capacity to abrogate chemokines secretion and limit the
inﬁltration of immune cells into infective sites. This may
impede the progression and aggravation of inﬂammation
given the migration of immune cells plays an important role
in the outcome of lung inﬁltration and ﬁbrosis. This is the
ﬁrst report oﬀering the possibility of using this botanical
extract or a biomimetic mixture of quinazoline alkaloids
(especially Evo and Rut) to act synergistically to ameliorate
chronic inﬂammatory conditions following H1N1 infection.
Funding
Grant NRICM-98-DBCMR from the National Research
Institute of Chinese Medicine (to W.F.C.).
References
[1] D. Us, “Cytokine storm in avian inﬂuenza,” Mikrobiyoloji
Bulteni, vol. 42, no. 2, pp. 365–380, 2008.
[ 2 ]C .A .B o n v i l l e ,H .F .R o s e n b e r g ,a n dJ .B .D o m a c h o w s k e ,
“Macrophage inﬂammatory protein-1α and RANTES are
present in nasal secretions during ongoing upper respiratory
tract infection,” Pediatric Allergy and Immunology, vol. 10, no.
1, pp. 39–44, 1999.Evidence-Based Complementary and Alternative Medicine 9
[3] N.-K. Mak, C.-Y. Leung, X.-Y. Wei et al., “Inhibition of
RANTES expression by indirubin in inﬂuenza virus-infected
human bronchial epithelial cells,” Biochemical Pharmacology,
vol. 67, no. 1, pp. 167–174, 2004.
[4] M. Adachi, S. Matsukura, H. Tokunaga, and F. Kokubu,
“Expression of cytokines on human bronchial epithelial cells
induced by inﬂuenza virus A,” International Archives of Allergy
and Immunology, vol. 113, no. 1-3, pp. 307–311, 1997.
[5] S. Matsukura, F. Kokubu, H. Kubo et al., “Expression of
RANTES by normal airway epithelial cells after inﬂuenza
virus A infection,” American Journal of Respiratory Cell and
Molecular Biology, vol. 18, no. 2, pp. 255–264, 1998.
[ 6 ]H .M .C h a n ga n dP .P .H .B u t ,Pharmacology and Application
of Chinese Material Medica, World Scientiﬁc, Singapore, 1987.
[7] W. Tang and G. Eisenbrand, “Evodia rutaecarpa (Juss)Benth,”
in Chinese Drugs of Plant Origin, W. Tang and G. Eisenbrand,
Eds., pp. 509–514, Springer, Berlin, Germany, 1992.
[8] W.-F. Chiou, Y.-J. Sung, J.-F. Liao, A. Y.-C. Shum, and
C.-F. Chen, “Inhibitory eﬀect of dehydroevodiamine and
evodiamine on nitric oxide production in cultured murine
macrophages,” Journal of Natural Products,v o l .6 0 ,n o .7 ,p p .
708–711, 1997.
[ 9 ]W .F .C h i o u ,H .C .K o ,C .F .C h e n ,a n dC .J .C h o u ,“ Evodia
rutaecarpa protects against circulation failure and organ
dysfunction in endotoxaemic rats through modulating nitric
oxide release,” Journal of Pharmacy and Pharmacology, vol. 54,
no. 10, pp. 1399–1405, 2002.
[10] C. P. Chang, J. Y. Chang, F. Y. Wang, J. Tseng, and J. G. Chang,
“The eﬀect of Evodia rutaecarpa extract on cytokine secretion
by human mononuclear cells in vitro,” American Journal of
Chinese Medicine, vol. 23, no. 2, pp. 173–180, 1995.
[ 1 1 ]Y .H .C h o i ,E .M .S h i n ,Y .S .K i m ,X .F .C a i ,J .J .L e e ,a n dH .P .
Kim, “Anti-inﬂammatory principles from the fruits of Evodia
rutaecarpa and their cellular action mechanisms,” Archives of
Pharmacal Research, vol. 29, no. 4, pp. 293–297, 2006.
[12] H. Matsuda, M. Yoshikawa, M. Iinuma, and M. Kubo,
“Antinociceptive and anti-inﬂammatory activities of limonin
isolated from the fruits of Evodia rutaecarpa var. bodinieri,”
Planta Medica, vol. 64, no. 4, pp. 339–342, 1998.
[13] D .B.Y ar osh,J .W .Galvin,S.L.N ay ,A.V .P e˜ na,M.T. Canning,
and D. A. Brown, “Anti-inﬂammatory activity in skin by
biomimetic of Evodia rutaecarpa extract from traditional
Chinese medicine,” Journal of Dermatological Science, vol. 42,
no. 1, pp. 13–21, 2006.
[14] H.-C. Ko, Y.-H. Wang, K.-T. Liou et al., “Anti-inﬂammatory
eﬀects and mechanisms of the ethanol extract of Evodia
rutaecarpa and its bioactive components on neutrophils and
microglial cells,” European Journal of Pharmacology, vol. 555,
no. 2-3, pp. 211–217, 2007.
[15] H. C. Ko, K. T. Chen, C. J. Chou, and C. F. Chen, “Determi-
nation of dehydroevodiamine, evodiamine, rutaecarpine and
synephrine in Evodia genus plants from Taiwan and mainland
China,” The Journal of Chinese Medicine, vol. 13, pp. 151–157,
2002.
[16] H.-C. Ko, K.-T. Chen, C.-J. Chou, Y.-J. Chang, G.-J. Wang,
and C.-F. Chen, “Quantitatively evaluation of bioactive com-
ponents of Evodia rutaecarpa (Tetradium ruticarpum) in
diﬀerent harvesting times,” Chinese Pharmaceutical Journal,
vol. 55, no. 5, pp. 305–312, 2003.
[17] L. C. Lin, C. J. Chou, K. T. Chen, and C. F. Chen, “Flavonoids
from Evoidae Fructus,” The Journal of Chinese Medicine,v o l .2 ,
pp. 94–100, 1991.
[ 1 8 ]Y .L .H u a n g ,S .H .L o k e ,C .C .H s u ,a n dW .F .C h i o u ,
“(+)-Vitisin A inhibits inﬂuenza a virus-induced RANTES
production in 549 alveolar epithelial cells through interfering
with Akt andSTAT1 phosphorylation,” Planta Medica, vol. 74,
pp. 156–162, 2008.
[19] H.-C. Ko, B.-L. Wei, and W.-F. Chiou, “Dual regulatory eﬀect
of plant extracts of Forsythia suspense on RANTES and MCP-
1 secretion in inﬂuenza A virus-infected human bronchial
epithelial cells,” Journal of Ethnopharmacology, vol. 102, no. 3,
pp. 418–423, 2005.
[20] M.-J. Don, J.-F. Liao, L.-Y. Lin, and W.-F. Chiou, “Cryp-
totanshinone inhibits chemotactic migration in macrophages
through negative regulation of the PI3K signaling pathway,”
British Journal of Pharmacology, vol. 151, no. 5, pp. 638–646,
2007.
[21] H.-R. Tsai, L.-M. Yang, W.-J. Tsai, and W.-F. Chiou, “Andro-
grapholide acts through inhibition of ERK1/2 and Akt phos-
phorylation to suppress chemotactic migration,” European
Journal of Pharmacology, vol. 498, no. 1-3, pp. 45–52, 2004.
[22] H. M. Chang and P. P. H. But, Pharmacology and Application
of ChineseMaterial Medica,vol.1,WorldScientiﬁc,Singapore,
1987.
[23] T. C. Moon, M. Murakami, I. Kudo et al., “A new class
of COX-2 inhibitor, rutaecarpine from Evodia rutaecarpa,”
Inﬂammation Research, vol. 48, no. 12, pp. 621–625, 1999.
[24] Y.-N. Liu, S.-L. Pan, C.-H. Liao et al., “Evodiamine
represses hypoxia-induced inﬂammatory proteins expression
and hypoxia-inducible factor 1α accumulation in RAW264.7,”
Shock, vol. 32, no. 3, pp. 263–269, 2009.
[25] S. Matikainen, J. Pirhonen, M. Miettinen et al., “Inﬂuenza
A and Sendai viruses induce diﬀerential chemokine gene
expression and transcription factor activation in human
macrophages,” Virology, vol. 276, no. 1, pp. 138–147, 2000.
[26] L. H. Thomas, J. S. Friedland, M. Sharland, and S. Becker,
“Respiratory syncytial virus-induced RANTES production
from humanbronchial epithelial cells is dependent on nuclear
factor-oB nuclear binding and is inhibited by adenovirus-
mediated expression of inhibitor of oB±,” Journal of Immunol-
ogy, vol. 161, no. 2, pp. 1007–1016, 1998.
[ 2 7 ]Y .T a k a d a ,Y .K o b a y a s h i ,a n dB .B .A g g a r w a l ,“ E v o d i a m i n e
abolishes constitutive and inducible NF-κBa c t i v a t i o nb y
inhibiting IκBα kinase activation, thereby suppressing NF-
κB-regulated antiapoptotic and metastatic gene expression,
up-regulating apoptosis, and inhibiting invasion,” Journal of
Biological Chemistry, vol. 280, no. 17, pp. 17203–17212, 2005.
[28] M. BaggioliniandP. Loetscher,“Chemokinesin inﬂammation
and immunity,” Immunology Today, vol. 21, no. 9, pp. 418–
420, 2000.
[29] C. S. Hii, D. S. Anson, M. Costabile, V. Mukaro, K. Dunning,
and A. Ferrante, “Characterization of the MEK5-ERK5 mod-
ule in human neutrophils and its relationship to ERK1/ERK2
in the chemotactic response,” J o u r n a lo fB i o l o g i c a lC h e m i s t r y ,
vol. 279, no. 48, pp. 49825–49834, 2004.
[30] F. Niyonsaba, K. Iwabuchi, A. Someya et al., “A cathelicidin
family of human antibacterial peptide LL-37 induces mastcell
chemotaxis,” Immunology, vol. 106, no. 1, pp. 20–26, 2002.
[31] M. Ogasawara and H. Suzuki, “Inhibition by evodiamine of
hepatocyte growth factor-induced invasion and migration of
tumor cells,” Biological and Pharmaceutical Bulletin, vol. 27,
no. 4, pp. 578–582, 2004.
[32] M. Ogasawara, T. Matsubara, and H. Suzuki, “Inhibitory
eﬀects of evodiamine on in vitro invasion and experimental
lung metastasis of murine colon cancer cells,” Biological and
Pharmaceutical Bulletin, vol. 24, no. 8, pp. 917–920, 2001.10 Evidence-Based Complementary and Alternative Medicine
[33] M. Ogasawara, T. Matsunaga, S. Takahashi, I. Saiki, and
H. Suzuki, “Anti-invasive and metastatic activities of evodi-
amine,” Biological and Pharmaceutical Bulletin, vol. 25, no. 11,
pp. 1491–1493, 2002.
[34] S.-K. Heo, H.-J. Yun, H.-S. Yi, E.-K. Noh, and S.-D. Park,
“Evodiamine and rutaecarpine inhibit migration by LIGHT
via suppression of NADPH oxidase activation,” Journal of
Cellular Biochemistry, vol. 107, no. 1, pp. 123–133, 2009.